单剂NEPA对比阿瑞匹坦方案预防高致吐化疗所致恶心呕吐的随机III期研究
这项在亚洲开展的随机双盲III期研究纳入828例接受顺铂类高致吐化疗的初治患者,比较单剂口服NEPA与3天口服阿瑞匹坦/格拉司琼方案。结果显示NEPA在总体期完全缓解率非劣于阿瑞匹坦方案(73.8% vs 72.4%),且未使用解救药物的患者比例显著更高,安全性相似。
要点
- 单剂NEPA在总体期完全缓解率非劣于3天阿瑞匹坦/格拉司琼方案。
- NEPA组未使用解救药物的患者比例显著更高(96.6% vs 93.5%)。
- NEPA安全性良好,与阿瑞匹坦/格拉司琼方案相似。
核心结论
- 在预防高致吐化疗所致恶心呕吐方面,仅第1天给予单剂NEPA非劣于3天口服阿瑞匹坦/格拉司琼方案。
研究设计与样本
- 随机、双盲、III期研究,在亚洲开展,纳入828例接受顺铂类高致吐化疗的初治患者。
- 患者随机接受单剂口服NEPA或3天口服阿瑞匹坦/格拉司琼方案,所有患者同时在第1-4天口服地塞米松。
- 主要终点为总体期(0-120小时)完全缓解率,非劣效界值设为-10%。
主要发现
- 总体期完全缓解率:NEPA组73.8%,阿瑞匹坦/格拉司琼组72.4%,95%CI(-4.5%,7.5%)。
- 无呕吐率:NEPA组75.0%,阿瑞匹坦/格拉司琼组74.0%,95%CI(-4.8%,6.9%)。
- 无显著恶心率:NEPA组75.7%,阿瑞匹坦/格拉司琼组70.4%,95%CI(-0.6%,11.4%)。
- 未使用解救药物率:NEPA组96.6%,阿瑞匹坦/格拉司琼组93.5%,95%CI(0.2%,6.1%)。
- NEPA耐受性良好,安全性特征与阿瑞匹坦/格拉司琼方案相似。
临床怎么用
- 对于接受顺铂类高致吐化疗的患者,可考虑使用单剂NEPA方案预防化疗所致恶心呕吐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Co-administration of multiple antiemetics that inhibit several molecular pathways involved in emesis is required to optimize chemotherapy-induced nausea and vomiting (CINV) control in patients receiving highly emetogenic chemotherapy (HEC). NEPA, a fixed combination of a highly selective NK1 receptor antagonist, netupitant (300 mg), and the pharmacologically distinct 5-HT3RA, palonosetron (PALO 0.50 mg), has shown superior CINV prevention compared with PALO in cisplatin and anthracycline/cyclophosphamide-based settings. This study is the first head-to-head comparison of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen. PATIENTS AND METHODS: This randomized, double-blind phase III study conducted in Asia was designed with the primary objective to demonstrate non-inferiority of a single oral dose of NEPA compared with a 3-day oral APR/GRAN regimen in chemotherapy-naïve patients receiving cisplatin-based HEC. All patients also received oral dexamethasone (DEX) on days 1-4. The primary efficacy endpoint was complete response (CR: no emesis/no rescue medication) during the overall (0-120 h) phase. Non-inferiority was defined as a lower 95% CI greater than the non-inferiority margin set at - 10%. Secondary efficacy endpoints included no emesis, no rescue medication, and no significant nausea (NSN). RESULTS: Treatment groups were comparable for the 828 patients analyzed: predominantly male (71%); mean age 54.5 years; ECOG 0-1 (98%); lung cancer (58%). NEPA demonstrated non-inferiority to APR/GRAN for overall CR [NEPA 73.8% versus APR/GRAN 72.4%, 95% CI (-4.5%, 7.5%)]. No emesis [NEPA 75.0% versus APR/GRAN 74.0%, 95% CI (-4.8%, 6.9%)] and NSN rates [NEPA 75.7% versus APR/GRAN 70.4%, 95% CI (-0.6%, 11.4%)] were similar between groups, but significantly more NEPA patients did not take rescue medication [NEPA 96.6% versus APR/GRAN 93.5%, 95% CI (0.2%, 6.1%)]. NEPA was well tolerated with a similar safety profile to APR/GRAN. CONCLUSIONS: In this first study comparing NK1RA regimens and DEX, NEPA administered only on day 1 was non-inferior to a 3-day oral APR/GRAN regimen in preventing CINV associated with HEC.
引用
- Zhang L, Lu S, Feng J, et al. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol. 2018. PMID: 29092012. doi:10.1093/annonc/mdx698
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。